Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

The invention provides protected ortho-quinone compounds comprising a group represented by:

##STR00001## where Ar is optionally substituted phenylene, X is selected from NH.sub.2, OH and SH, and the protected forms of each, W is optionally substituted methylene, such as methylene, and d is a double or single bond, and the salts and solvates thereof

The invention provides protected ortho-quinone compounds comprising a group represented by:

##STR00001## where Ar is optionally substituted phenylene, X is selected from NH.sub.2, OH and SH, and the protected forms of each, W is optionally substituted methylene, such as methylene, and d is a double or single bond, and the salts and solvates thereof